The resignation of the FDA's head drug regulator George Tidmarsh comes amid concerns about conduct related to lupus nephritis drug Lupkynis.
As RFK Jr.–era turbulence deepens and regulators jump ship, attention has turned to how long the agency can hold the line.
With its Q3 2025 results on Tuesday, Aurinia Pharmaceuticals (AUPH) said that it recently responded to an information request ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback